Señales en vivo de HNSA.ST | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 may 2024 @ 11:29):

Stats
Volumen de hoy	117 319
Volumen promedio	139 591
Capitalización de mercado	2.30B
EPS	SEK0 ( 2024-04-17 )
Próxima fecha de ganancias	( SEK-2.78 ) 2024-07-17
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-2.27
ATR14	SEK0.0930 (0.25%)

Volumen Correlación

Largo: -0.19 (neutral)

Corto: -0.26 (neutral)

Signal:(43.607) Neutral

Hansa Biopharma AB (publ) Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Hansa Biopharma AB (publ) Correlación - Moneda/Commodity

-0.45
( neutral )

-0.50
( neutral )

-0.49
( neutral )

-0.60
( weak negative )

-0.47
( neutral )

0.31
( neutral )

Hansa Biopharma AB (publ) Finanzas

Annual	2023
Ingresos:	SEK134.09M
Beneficio Bruto:	SEK69.27M (51.65 %)
EPS:	SEK-15.83

FY	2023
Ingresos:	SEK134.09M
Beneficio Bruto:	SEK69.27M (51.65 %)
EPS:	SEK-15.83

FY	2022
Ingresos:	SEK154.53M
Beneficio Bruto:	SEK116.05M (75.10 %)
EPS:	SEK-13.60

FY	2021
Ingresos:	SEK33.88M
Beneficio Bruto:	SEK18.45M (54.47 %)
EPS:	SEK-12.33

Financial Reports:

No articles found.

Hansa Biopharma AB (publ) Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.